Impact of co-existent thyroiditis on clinical outcome in papillary thyroid carcinoma with high preoperative serum antithyroglobulin antibody: a retrospective cohort study.
OBJECTIVE
The aim of this study was to investigate the impact of co-existent chronic lymphocytic thyroiditis (CLT) on changes in serum antithyroglobulin antibody (TgAb) and clinical outcome in papillary thyroid carcinoma (PTC) patients with high preoperative serum TgAb.


METHODS
A retrospective cohort study.


METHODS
University teaching hospital.


METHODS
Thirty-seven PTC patients with high preoperative serum TgAb level (≥100 U/mL) were evaluated. All patients underwent total thyroidectomy followed by high-dose I-131 ablation.


METHODS
Per cent changes of TgAb between pre-treatment and post-treatment, and disease-free survival were calculated.


RESULTS
Twenty-two patients (59.5%) had co-existent CLT, and seven had residual/recurrent tumours. There was a higher proportion of females among the patients with CLT compared to those without CLT (95.5% versus 66.7%; P = 0.0306). There were trends towards more aggressive pathologies, such as tumour size, extrathyroidal extension, surgical margin and lymph node stage, in PTC without CLT than in that with co-existent CLT. Pre-treatment and post-treatment TgAb were all higher in PTC with co-existent CLT. But, per cent changes of TgAb between pre-treatment and post-treatment were no significant difference between PTC with and without CLT (P < 0.05). Patients with co-existent CLT showed a significantly lower residual/recurrent tumour rate than those without CLT (4.5% versus 40%; P = 0.0113).


CONCLUSIONS
Residual/recurrent tumour rate was lower in PTC patients with co-existent CLT than in those without CLT.
Department of Nuclear Medicine, Samsung Changwon Hospital, Sungkyunkwan University School of Medicine, Changwon, Korea.
H-Y
HY
Nam
Department of Pathology, Samsung Changwon Hospital, Sungkyunkwan University School of Medicine, Changwon, Korea.
H Y
HY
Lee
Department of Otolaryngology, Samsung Changwon Hospital, Sungkyunkwan University School of Medicine, Changwon, Korea.
G C
GC
Park
D000293:Adolescent; D000328:Adult; D000368:Aged; D001323:Autoantibodies / Q000097:blood*; D014408:Biomarkers, Tumor / Q000097:blood; D002291:Carcinoma, Papillary / Q000097:blood* / Q000150:complications* / Q000473:pathology / Q000628:therapy; D005260:Female; D050031:Hashimoto Disease / Q000097:blood* / Q000150:complications* / Q000473:pathology / Q000628:therapy; D006801:Humans; D007457:Iodine Radioisotopes / Q000627:therapeutic use; D008297:Male; D008875:Middle Aged; D009364:Neoplasm Recurrence, Local; D018365:Neoplasm, Residual; D012189:Retrospective Studies; D013954:Thyroglobulin / Q000097:blood; D013964:Thyroid Neoplasms / Q000097:blood* / Q000150:complications* / Q000473:pathology / Q000628:therapy; D013965:Thyroidectomy; D013972:Thyrotropin / Q000097:blood
D001323:Autoantibodies; D014408:Biomarkers, Tumor; D007457:Iodine Radioisotopes; C006606:anti-thyroglobulin; D013972:Thyrotropin; D013954:Thyroglobulin